A heated debate is going on between Daewoong Pharmaceuticals and Medytox over a U.S. court’s decision on their botulinum toxin (BTX) strain.
Medytox메디톡스 filed a suit against Daewoong and its U.S. partner Alphaeon for allegedly stealing the company’s botulinum toxin (BTX) strain to produce Nabota, an anti-wrinkle treatment. But the California court put the case on hold.
Daewoong대웅제약 had criticized the suit saying it was a strategy to slow Nabota’s entrance to the U.S. market. "The U.S. court’s decision has facilitated Nabota's entry into advanced countries,” the company said in a press release. “The decision has also recovered the trust in the Korean pharmaceutical and bio industry, which was threatened by the lawsuit.”
Medytox refutes Daewoong’s claim saying that the court had put a hold on the case until it can ascertain the case from the Korean court.
“The court will decide whether to resume the case after a conference on April 13 next year,” said a Medytox official. “Our company will be following up on the U.S. court’s minute order and will file legal action in Korea.”
The case has to obtain objective and scientific judgments by holding an open discussion with interested parties and related experts, he added.
<© Korea Biomedical Review, All rights reserved.>